NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital leads $67.5 million (€64.4 million) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease
Proceeds of financing will support two double-blinded Phase 2 trials for its lead candidate XC001, a pioneering transformative gene therapy approach for the treatment of severe cardiovascular disease. This investment builds on Jeito's expertise in cardiology,...
Find all our press releases
Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials
Investment will support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trial for...
Dr Rafaèle Tordjman Receives L’Agefi’s Prestigious 2024 ‘AM Leader’ Award
Paris, France, November 22nd 2024 - Jeito is pleased to announce that Dr Rafaèle Tordjman has...
Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 (CLDN1) ADCs in solid tumors
Building on its co-lead investments in Alentis Therapeutics’ Series B (2021) and Series C (2023)...
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
This new financing will support broad late-stage clinical development program for visugromab,...
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion
This acquisition reflects the significant clinical progress achieved with Restoret™,EyeBio’s novel...
Jeito Capital announces acquisition of portfolio company HI-Bio™ by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 billion; Biogen to strengthen portfolio to help patients with severe immune-mediated disease
Biogen Inc. (Nasdaq: BIIB) to acquire HI-Bio™ for a total consideration of up to $1.8 billion...
Face to face
Meet Jeito
16-17
December
All day long
Conference of Paris 2024
Jeito will be present at the Conference of Paris 2024, for its 8th edition around the theme “Confronting the Unknown”, encouraging leaders to share their knowledge and understanding of global economic, social and environmental issues as a way to collaborate and collectively overcome these challenges.
13-16
January
All day long
JPM Healthcare Conference 2025
Jeito will be present at the 43rd JPM Healthcare Conference 2025, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.
28-30
January
All day long
IPEM Cannes 2025
Jeito will be present at the 11th edition of IPEM Cannes – Wealth 2025, gathering Private Capital key decision-makers and incubating this year “IPEM Wealth”, a brand-new format designed to support the democratization of Private Markets, in Cannes.